This study adds to the body of literature supporting the beneficial effects of semaglutide in people with overweight and obesity without diabetes, which is so necessary as we continue to navigate the complex landscape of insurance coverage of these medications in people who do not have diabetes, Shiara Ortiz-Pujols, MD, MPH, an obesity medicine physician at Staten Island University Hospital, told Healthline
The major regulator of autophagy is the mechanistic (also known as mammalian) target of rapamycin (mTOR) signaling, which is closely associated with the activity of mitochondria
Tirzepatide, originally approved for type 2 diabetes, has shown promising results in weight management
Tirzepatide works partly by dramatically reducing appetite
There is no established direct pharmacological mechanism by which semaglutide would cause erectile dysfunction
Quality variation: Compounded medications are prepared by individual pharmacies, and quality can vary